Muted Sanofi hits fresh 52-week low, shares trade well below analyst targets
22.06.2026 - 20:57:56 | ad-hoc-news.de
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-22, 20:53.
Sanofi (FR0000127771) set a new 52-week low on Euronext Paris on Monday, with the shares touching 71.50 euros during the session according to market data from the Financial Times.FT equity summary for Sanofi The French pharma group remains a heavyweight in the CAC 40 and Euro Stoxx 50, but its stock trades markedly below recent analyst targets.
What the latest trading shows
The Sanofi shares traded around 72.79 euros at 15:00 on Euronext Paris, down about 1.8 percent on the day, with intraday data confirming the 52-week range between 71.50 and 91.15 euros.MarketScreener quote and range data This places the stock more than 20 percent below its 52-week high recorded in October 2025.
The move comes despite Sanofi’s market capitalization still exceeding 90 billion euros and a relatively low beta around 0.3 on its US-listed ADR, signaling more muted volatility than the broader market.StockAnalysis overview for Sanofi ADR On Euronext Paris, daily volumes on Monday reached more than 330,000 shares traded by mid-afternoon, according to exchange-based data.
Analyst targets stay far above spot
Analyst consensus remains clearly more optimistic than the current price suggests, with Deutsche Bank Research recently reiterating a Buy rating and setting a 95 euro target for the Paris-listed shares in a note summarized on June 15.MarketScreener analyst consensus for Sanofi Other brokers in the same compilation cluster mostly around Buy or Outperform recommendations.
For the US ADR listed on NASDAQ, a composite of analyst projections cited by StockAnalysis points to an average price target of 55.90 dollars, implying around 32 percent upside from recent levels near 42 dollars.StockAnalysis consensus and target data The ADR carries an indicated dividend yield of roughly 4 percent based on a 1.76 dollar annual payout.
All news and data on the Sanofi shares
Current coverage, historical prices and background reports help investors assess how the Sanofi shares trade versus their sector peers and analyst expectations.
R&D leadership change and pipeline focus
Sanofi announced the appointment of Paulo Fontoura as Executive Vice President and Global Head of R&D in a press release dated June 22, 2026, underscoring CEO Paul Hudson’s emphasis on accelerating the pipeline.Sanofi IR release on Paulo Fontoura appointment Fontoura brings prior experience from senior roles in immunology and neuroscience at global pharmaceutical peers.
The new R&D head takes over after Sanofi flagged setbacks in some late-stage programs in 2025, prompting an internal review of development priorities and capital allocation. Management has since stressed a more focused portfolio, with diabetes, immunology and oncology as core growth pillars in investor presentations.
Regulatory wins in Japan and the US
Recent news flow also includes regulatory advances, as Japan’s Ministry of Health, Labour and Welfare approved the subcutaneous formulation of Sanofi’s multiple myeloma therapy Sarclisa in combination regimens on June 19, expanding treatment options in a key oncology market.Sanofi press release on Sarclisa SC approval in Japan The formulation is designed to shorten administration times compared with the intravenous version.
Just days earlier, the US Food and Drug Administration granted approval for Tzield as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes, extending an earlier label that focused on delaying onset.Sanofi announcement on expanded Tzield indication These approvals support Sanofi’s strategy to deepen its specialty care franchise alongside established vaccines and primary care products.
The therapies behind the Sanofi name
Sanofi generates a large share of its revenue with blockbuster drugs such as the eczema and asthma treatment Dupixent and its portfolio of diabetes therapies, complemented by vaccines from its Sanofi Vaccines unit. The company also markets oncology products like Sarclisa and rare disease treatments that aim for higher-margin specialty segments.
Where the Sanofi shares trade now
The Sanofi shares (FR0000127771) trade on 2026-06-22, 15:00, on Euronext Paris at 72.79 euros.
Key data on the Sanofi shares
- Company: Sanofi S.A.
- ISIN: FR0000127771
- WKN: 920657
- Ticker: SAN
- Trading venue: Euronext Paris
- Price (as of 2026-06-22, 15:00): 72.79 EUR
- Market cap: approximately 92 billion EUR (as of 2026-06-22)
- Sector / industry: Pharmaceuticals & Biotechnology
- Index membership: CAC 40, Euro Stoxx 50, Stoxx Europe 600
- Next earnings date: not officially scheduled
Disclaimer: This article is for informational purposes only and does not constitute investment advice, a recommendation to buy or sell any security, or any other form of financial guidance. All data are based on publicly available sources considered reliable but are not guaranteed for accuracy or completeness.
